Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57

Piper Jaffray Raises Price Target on Amgen (AMGN) to $200 Following 2Q EPS Beat

July 31, 2015 10:47 AM EDT

Piper Jaffray reiterated an Overweight rating on Amgen (NASDAQ: AMGN), and raised the price target to $200.00 (from $192.00), following 2Q earnings results. Total revenue of $5.37B was ahead of consensus by $64M. EPS of $2.57 beat estimates by $0.16 aided by lower than expected R&D.... More

Amgen (AMGN) PT Raised to $193 at Cowen Post Q2

July 31, 2015 6:46 AM EDT

Cowen analyst Eric Schmidt reiterated an Outperform rating and boosted his price target on Amgen (NASDAQ: AMGN) to $193.00 (from $189.00) amid better-than-expected Q2 results.

Schmidt commented, "Amgen reported above-consensus Q2 revenue ($5.37B vs. $5.31BE) and non-GAAP EPS ($2.57 vs. $2.41E), and raised 2015 revenue... More

Amgen (AMGN) Tops Q2 EPS by 14c, Raises FY Guidance

July 30, 2015 4:05 PM EDT

Amgen (NASDAQ: AMGN) reported Q2 EPS of $2.57, $0.14 better than the analyst estimate of $2.43. Revenue for the quarter came in at $5.37 billion versus the consensus estimate of $5.32 billion.

Second Quarter 2015 Product Sales Performance

Total product sales increased 6 percent for the second quarter of 2015 versus the second quarter of 2014. The increase was driven primarily by ENBREL, Prolia, Sensipar, Kyprolis and XGEVA. Growth for the... More